Eisai (ESALY) and Merck (MRK) announced that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy. Treatment options for this type of liver cancer are limited, and the prognosis is poor. LENVIMA is the first new, first-line treatment for advanced or unresectable HCC in a decade to show an overall survival treatment effect by statistical confirmation of non-inferiority against standard of care.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.